| Title | α-Labeling of J591, an Antibody Targeting Prostate-Specific Membrane Antigen: The Technique and Considerations from the First Dedicated Production Lab at an Academic Institution in the United States. |
| Publication Type | Journal Article |
| Year of Publication | 2023 |
| Authors | Subramanian K, Stangl-Kremser J, Sawoszczyk L, Avlonitis V, Gernerd A, Nixon K, Zgaljardic M, Tagawa S, Bander N, Osborne JR |
| Journal | J Nucl Med Technol |
| Volume | 51 |
| Issue | 3 |
| Pagination | 215-219 |
| Date Published | 2023 Sep |
| ISSN | 1535-5675 |
| Keywords | Humans, Male, Positron-Emission Tomography, Prostate, Prostatic Neoplasms, Radiopharmaceuticals, United States, Universities |
| Abstract | The protein expression of the prostate-specific membrane antigen correlates with unfavorable or aggressive histologic features of prostate cancer, resulting in use as a diagnostic PET imaging radiotracer and therapeutic target. Here, we discuss the methods to develop 225Ac-DOTA-J591, an α-labeled compound targeting an extracellular epitope of prostate-specific membrane antigen, which is currently being studied in early clinical trials. In addition, we review quality control, radiation safety measures, and clinical considerations before administration of this radioimmunotherapeutic agent. |
| DOI | 10.2967/jnmt.122.265166 |
| Alternate Journal | J Nucl Med Technol |
| PubMed ID | 37163648 |
Related Institute:
Molecular Imaging Innovations Institute (MI3)